Medical Oncology

Prof. Dr. Mesut Şeker

Doctor and researcher Medipol Mega Üniversite Hastanesi İstanbul
Lung NeoplasmsStomach NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsAdenocarcinomaLiver NeoplasmsLymphoma, B-Cell, Marginal ZoneOvarian NeoplasmsNeoplasms, Multiple PrimaryBrain NeoplasmsColonic NeoplasmsNeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCOVID-19Neoplasms, Germ Cell and EmbryonalTeratomaTesticular NeoplasmsCarcinoma, Renal CellKidney NeoplasmsPancreatic NeoplasmsSkin NeoplasmsGallbladder NeoplasmsGastrointestinal NeoplasmsCarcinoma, Signet Ring CellCarcinoma, Squamous CellPregnancy Complications, NeoplasticLymphoma, Large B-Cell, DiffuseConjunctival NeoplasmsLymphoma, Non-Hodgkin
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Lung Neoplasms 20 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Stomach Neoplasms 19 publications
  • Breast Neoplasms 17 publications
  • Carcinoma, Non-Small-Cell Lung 10 publications
  • Colorectal Neoplasms 8 publications
  • Adenocarcinoma 7 publications
  • Liver Neoplasms 5 publications
  • Lymphoma, B-Cell, Marginal Zone 5 publications
  • Ovarian Neoplasms 4 publications
  • Neoplasms, Multiple Primary 3 publications
  • Brain Neoplasms 3 publications
  • Colonic Neoplasms 3 publications
  • Neoplasms 3 publications
  • Carcinoma, Ductal, Breast 3 publications
  • Carcinoma, Lobular 3 publications
  • COVID-19 2 publications
  • Neoplasms, Germ Cell and Embryonal 2 publications
  • Teratoma 2 publications
  • Testicular Neoplasms 2 publications
  • Carcinoma, Renal Cell 2 publications
  • Kidney Neoplasms 2 publications
  • Pancreatic Neoplasms 2 publications
  • Skin Neoplasms 2 publications
  • Gallbladder Neoplasms 2 publications
  • Gastrointestinal Neoplasms 2 publications
  • Carcinoma, Signet Ring Cell 2 publications
  • Carcinoma, Squamous Cell 2 publications
  • Pregnancy Complications, Neoplastic 2 publications
  • Lymphoma, Large B-Cell, Diffuse 2 publications
  • Conjunctival Neoplasms 2 publications
  • Lymphoma, Non-Hodgkin 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: medipol.com.tr.

  • TIBBİ ONKOLOJİ
  • MEME KANSERLERİ
  • GASTROİNTESTİNAL SİSTEM KANSERLERİ
  • AKCİĞER KANSERLERİ
  • GENİTOÜRİNER SİSTEM KANSERLERİ
  • İMMÜNOTERAPİ VE HEDEFE YÖNELİK TEDAVİLER
  • KLİNİK ARAŞTIRMALAR
  • DESTEK TEDAVİLERİ VE KİŞİYE ÖZEL ONKOLOJİ

CV

Education and experience

From source

Prof. Dr. Mesut Şeker, 1972 yılında doğmuştur. Tıp eğitimini 1996 yılında Çukurova Üniversitesi Tıp Fakültesi'nde tamamlamıştır. İç Hastalıkları uzmanlık eğitimini Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi'nde tamamlayarak 2003 yılında İç Hastalıkları Uzmanı olmuştur. 2011 yılında aynı kurumda Tıbbi Onkoloji yan dal uzmanlığını tamamlamıştır. İç Hastalıkları uzmanlık tezini nonalkolik yağlı karaciğer hastalığında insülin direnci üzerine, Tıbbi Onkoloji yan dal tezini ise diffüz büyük B hücreli lenfomada prognostik belirteçler üzerine hazırlamıştır.Uzmanlık eğitiminin ardından devlet hizmet yükümlülüğünü Tekirdağ Devlet Hastanesi Tıbbi Onkoloji Bölümü'nde yerine getirmiştir. 2013 yılında Doçent, 2018 yılında Profesör unvanını almıştır. Mesleki kariyeri boyunca Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Bezmialem Vakıf Üniversitesi ve Medipol Üniversitesi'nde akademik ve klinik görevlerde bulunmuştur.Ulusal ve uluslararası çok sayıda kongre, kurs ve bilimsel toplantıda konuşmacı ve araştırmacı olarak yer almış; çok sayıda SCI kapsamındaki bilimsel yayına katkı sağlamıştır. Bilimsel birikimini güncel tanı ve tedavi yöntemleriyle birleştiren Prof. Dr. Mesut Şeker, her hastasını bireysel olarak değerlendirerek kişiye özel tanı ve tedavi planlamasını benimsemektedir.

Experience

  • 2018 - 2025Bezmialem Vakıf ÜniversitesiProf.Dr.
  • 2014 - 2018Bezmialem Vakıf ÜniversitesiDoç.Dr.
  • 2014 - 2014Medipol ÜniversitesiDoç.Dr.
  • 2013 - 2014Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma HastanesiDoç.Dr.
  • 2011 - 2013Tekirdağ Devlet HastanesiUzm.Dr.
  • 2006 - 2008Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma HastanesiUzm.Dr.

Education

  • 2011İstanbul Kartal Dr.Lütfi Kırdar Eğitim ve Araştırma Hastanesi, Tıbbi Onkolojimedipol.com.tr
  • 2003İstanbul Kartal Dr.Lütfi Kırdar Eğitim ve Araştırma Hastanesi, İç Hastalıklarımedipol.com.tr
  • 1996Çukurova Üniversitesi, Tıp Fakültesimedipol.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologymedipol.com.trFrom source
  • InstitutionMedipol Mega Üniversite Hastanesimedipol.com.trFrom source
  • Area of workLung NeoplasmsExtracted from 20 publications · Model version —From source
  • Publications165 publicationsOpenAlexFrom source
  • Languagesİngilizcemedipol.com.trFrom source
  • Last synchronised4 November 2026 20:22https://medipol.com.tr/doktorlarimiz/profdr-mesut-sekermedipol.com.tr

Scientific work

Publications on Lung Neoplasms

165 publications

  1. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Open-access full textSource: OpenAlex

  2. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Open-access full textSource: OpenAlex

  3. Association between depression and low skeletal muscle mass in patients with newly diagnosed lung cancer

    Frontiers in Psychology, 2026

    DOI 10.3389/fpsyg.2026.1829410 PMID 42293931 Open-access full textSource: OpenAlex

  4. Clinical Features and Survival Outcomes in Primary Intestinal Lymphoma: A Multicenter Retrospective Study

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612646 Source: OpenAlex

  5. Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors

    Medicina, 2025

    DOI 10.3390/medicina61071279 PMID 40731908 Open-access full textSource: OpenAlex

  6. The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14186536 PMID 41010740 Open-access full textSource: OpenAlex

  7. Prevalence and co-incidence of geriatric syndromes according to the ECOG performance status in older cancer patients

    Frontiers in Medicine, 2024

    DOI 10.3389/fmed.2024.1331246 PMID 38439897 12 citations (Europe PMC) Open-access full textSource: OpenAlex

  8. Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram

    Supportive Care in Cancer, 2024

    DOI 10.1007/s00520-024-08702-0 PMID 38976108 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  9. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2358458 PMID 38803194 Source: OpenAlex

  10. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

    Current Problems in Cancer, 2024

    DOI 10.1016/j.currproblcancer.2024.101102 PMID 38735211 2 citations (Europe PMC) Source: OpenAlex

View all 165 publications